Bruker Corporation $BRKR Shares Bought by Vaughan Nelson Investment Management L.P.

Vaughan Nelson Investment Management L.P. lifted its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 61.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,090,155 shares of the medical research company’s stock after acquiring an additional 796,510 shares during the quarter. Vaughan Nelson Investment Management L.P. owned 1.38% of Bruker worth $67,909,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Orbis Allan Gray Ltd purchased a new stake in Bruker during the 2nd quarter worth approximately $192,735,000. AQR Capital Management LLC increased its stake in shares of Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after buying an additional 1,850,215 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new stake in Bruker in the second quarter valued at $62,032,000. Norges Bank bought a new position in Bruker during the 2nd quarter valued at $44,459,000. Finally, Royal London Asset Management Ltd. bought a new position in Bruker during the 2nd quarter valued at $32,478,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Wall Street Analysts Forecast Growth

BRKR has been the subject of several research analyst reports. Rothschild & Co Redburn started coverage on shares of Bruker in a research report on Thursday, November 20th. They issued a “buy” rating and a $60.00 target price for the company. Barclays lifted their price target on Bruker from $45.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Rothschild Redb raised Bruker to a “strong-buy” rating in a report on Thursday, November 20th. Redburn Partners set a $60.00 target price on Bruker in a report on Thursday, November 20th. Finally, TD Cowen lifted their target price on Bruker from $40.00 to $42.00 and gave the stock a “hold” rating in a research report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Bruker currently has an average rating of “Hold” and a consensus target price of $51.50.

Insider Transactions at Bruker

In other news, Director John A. Ornell sold 6,233 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the transaction, the director owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. The trade was a 15.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 27.30% of the company’s stock.

Bruker Price Performance

BRKR opened at $52.67 on Wednesday. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81. The company’s 50-day moving average price is $45.20 and its 200 day moving average price is $39.45. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $64.64. The firm has a market cap of $8.00 billion, a price-to-earnings ratio of -329.19, a price-to-earnings-growth ratio of 6.64 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.33 by $0.12. The company had revenue of $860.50 million during the quarter, compared to analyst estimates of $847.40 million. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The business’s revenue was down .5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, sell-side analysts expect that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Shareholders of record on Monday, December 8th were given a $0.05 dividend. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 annualized dividend and a yield of 0.4%. Bruker’s dividend payout ratio (DPR) is currently -125.00%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.